Discriminant Analysis of Main Prognostic Factors Associated with Hemodynamically Significant PDA: Apgar Score, Silverman–Anderson Score, and NT-Pro-BNP Level
Open Access
- 22 August 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (16) , 3729
Abstract
Hemodynamically significant patent ductus arteriosus (hsPDA) in premature newborns is associated with a risk of PDA-related morbidities. Classification into risk groups may have a clinical utility in cases of suspected hsPDA to decrease the need for echocardiograms and unnecessary treatment. This prospective observational study included 99 premature newborns with extremely low body weight, who had an echocardiogram performed within the first three days of life. Discriminant analysis was utilized to find the best combination of prognostic factors for evaluation of hsPDA. We used binary logistic regression analysis to predict the relationship between parameters and hsPDA. The cohort’s mean and standard deviation gestational age was 27.6 ± 2.55 weeks, the mean birth weight was 1015 ± 274 g. Forty-six (46.4%) infants had a PDA with a mean diameter of 2.78 mm. Median NT-pro-BNP levels were 17,600 pg/mL for infants with a PDA and 2773 pg/mL in the non-hsPDA group. The combination of prognostic factors of hsPDA in newborns of extremely low body weight on the third day of life was determined: NT-pro-BNP, Apgar score, Silverman–Anderson score (Se = 82%, Sp = 88%). A cut-off value of NT-pro-BNP of more than 8500 pg/mL can predict hsPDA (Se = 84%, Sp = 86%).Keywords
Funding Information
- Russian Foundation for Basic Research (20-41-596005)
- Ministry of Science and Higher Education of the Russian Federation (Program of activities of the Perm Scientific and Educational Center "Rational Subsoil Use")
This publication has 54 references indexed in Scilit:
- The pot calling the kettle black: the extent and type of errors in a computerized immunization registry and by parent reportBMC Pediatrics, 2014
- Functional echocardiography in staging for ductal disease severityEuropean Journal of Pediatrics, 2012
- Patent Ductus Arteriosus: Are Current Neonatal Treatment Options Better or Worse Than No Treatment at All?Seminars in Perinatology, 2012
- Can a clinical decision rule help ductus arteriosus management in preterm neonates?Acta Paediatrica, 2011
- Plasma C-Terminal Pro-Endothelin-1 and the Natriuretic Pro-Peptides NT-proBNP and MR-proANP in Very Preterm Infants with Patent Ductus ArteriosusNeonatology, 2011
- NT-Pro-B-Type Natriuretic Peptide Levels in Infants with Failure to Thrive due to Caloric DeprivationInternational Journal of Pediatrics, 2010
- Early N‐terminal pro‐brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infantsActa Paediatrica, 2009
- The Role of Patent Ductus Arteriosus Ligation in Bronchopulmonary Dysplasia: Reexamining a Randomized Controlled TrialThe Journal of Pediatrics, 2009
- The Ductus Arteriosus Rarely Requires Treatment in Infants > 1000 GramsAmerican Journal of Perinatology, 2008
- N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational studyArchives of Disease in Childhood - Fetal and Neonatal Edition, 2007